PI3K and AKT Isoforms in Immunity - Mechanisms and Therapeutic Opportunities (Hardcover, 1st ed. 2022)

This book provides an essential overview of the role of phosphoinositide-3-phosphate kinase (PI3K) isoforms in modulating the function of immune system cells and their involvement in disease. PI3K is a family of kinases involved in basic cellular processes such as proliferation, migration and cell death. Recent work has highlighted the multiple roles of PI3K classes and subunits and their involvement in the immune response to the body's own and foreign antigens and diseases such as cancer and autoimmunity. This book offers a detailed introduction to the biology of the three PI3K classes, followed by an extensive discussion of the diverse roles of AKT and PI3K isoforms in immune cells. Based on this knowledge, it subsequently explains in more detail how specific isoforms are connected to immune-mediated diseases. The book concludes by highlighting the latest advances in the production of isoform-specific inhibitors and their use in various human diseases. This book is intended as a reference guide for students and researchers interested in the multifaceted aspects of PI3K biology.

General

Imprint:	Springer International Publishing AG
Country of origin:	Switzerland
Series:	Current Topics in Microbiology and Immunology, 436
Release date:	October 2022
First published:	2022
Editors:	Margarita Dominguez-Villar
Dimensions:	235 x 155mm (L x W)
Format:	Hardcover
Pages:	466
Edition:	1st ed. 2022
ISBN-13:	978-3-03-106565-1
Categories:	Books > Science & Mathematics > Biology, life sciences > Cellular biology > General Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology > General Promotions
LSN:	3-03-106565-4
Barcode:	9783031065651

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!